Recurrent Hypoglycemia Without Diabetes or Clear Exposure

An adult has recurrent early-morning confusion, sweating, and tremor that improve after juice despite no diabetes diagnosis. A household member uses insulin, defensive eating has caused weight gain, and one home-meter value was low. The task is to document Whipple's triad with laboratory plasma glucose and obtain a critical sample during symptoms before attributing events to endogenous disease or covert exposure.

Case focus#

Treat neuroglycopenia immediately, but when safely possible draw glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and a sulfonylurea or meglitinide screen during the episode. Exclude critical illness, liver or kidney failure, adrenal insufficiency, alcohol or starvation, and medication exposure before localization imaging for insulinoma.

This analysis concentrates on calibration. It compares plausible explanations, asks which observations genuinely discriminate among them, and keeps the working diagnosis open to revision as new evidence arrives.

Problem representation#

The useful representation is not a label alone. It combines the tempo of the problem, the setting, the physiologic or functional threat, the evidence already available, and the important information that is still missing. For this nondiabetic hypoglycemia analysis, the working frame must remain broad enough to compare Endogenous hyperinsulinemic hypoglycemia, Exogenous insulin exposure, Secretagogue-associated hypoglycemia, Critical illness or adrenal insufficiency without allowing a familiar first impression to become an untested conclusion.

The setting materially changes the plan: An endocrine service with supervised fasting, rapid critical-sample processing, imaging after biochemical confirmation, and toxicology support.. Available monitoring, access to consultation, travel time, record continuity, and the reliability of follow-through alter what counts as a safe next step. A plan that is reasonable in a continuously monitored environment may be unsafe when results return after discharge or urgent reassessment is difficult.

Immediate safety priorities#

• Severe neuroglycopenia: Seizure, loss of consciousness, focal deficit, injury, prolonged confusion, or inability to take oral carbohydrate requires immediate parenteral glucose and monitored evaluation.
• Critical illness or hormone failure: Hypotension, sepsis, weight loss, hyperpigmentation, liver failure, kidney failure, malnutrition, or severe systemic illness can cause life-threatening hypoglycemia outside an insulinoma pathway.
• Recurrent unobserved exposure: Access to insulin or secretagogues, healthcare work, inconsistent critical samples, safeguarding concerns, or episodes limited to one environment requires neutral confidential exposure assessment.
• Unsafe fasting or driving risk: Events while driving, operating machinery, caring for dependents, overnight fasting, or living alone requires immediate activity restriction and a supervised diagnostic plan.

These findings are action signals rather than diagnostic shortcuts. They determine the pace of stabilization, consultation, and escalation while the causal analysis continues in parallel.

Prioritized differential diagnosis#

Endogenous hyperinsulinemic hypoglycemia#

What supports it. During low plasma glucose, inappropriately high insulin, C-peptide, and proinsulin with suppressed beta-hydroxybutyrate and a negative secretagogue screen supports insulinoma or endogenous beta-cell secretion.

What argues against it or keeps uncertainty open. Suppressed insulin and C-peptide during a verified episode excludes hyperinsulinemia and redirects to critical illness, hormone deficiency, or substrate failure.

Discriminating next step. Confirm the biochemical pattern during spontaneous or supervised fasting hypoglycemia, then localize with pancreas-directed imaging and advanced techniques only after proof.

Exogenous insulin exposure#

What supports it. High insulin with suppressed C-peptide and proinsulin during hypoglycemia, access to insulin, and low ketones supports administered insulin.

What argues against it or keeps uncertainty open. Detectable or elevated C-peptide and proinsulin during a reliable critical sample argues against pure exogenous insulin exposure.

Discriminating next step. Treat safely, verify assay limitations and insulin analog detection, obtain a nonaccusatory exposure history, and involve toxicology and behavioral or safeguarding care as indicated.

Secretagogue-associated hypoglycemia#

What supports it. High insulin and C-peptide with a positive sulfonylurea or meglitinide screen supports prescribed, accidental, contaminated, or undisclosed secretagogue exposure.

What argues against it or keeps uncertainty open. A high-quality negative drug screen covering relevant agents and timing lowers probability, but sampling and assay coverage must be reviewed.

Discriminating next step. Identify the exact agent and duration, monitor for recurrence, review household and pharmacy access, and prevent re-exposure without assuming intent.

Critical illness or adrenal insufficiency#

What supports it. Sepsis, liver failure, kidney failure, malnutrition, alcohol use, hypotension, hyponatremia, hyperkalemia, or low cortisol reserve can impair glucose production or clearance.

What argues against it or keeps uncertainty open. A well person with repeated fasting hyperinsulinemic critical samples and no organ or hormone abnormality makes these causes less likely.

Discriminating next step. Treat the underlying illness, obtain cortisol and other tests when clinically indicated, and do not localize the pancreas when insulin is appropriately suppressed.

Postprandial hypoglycemic syndrome#

What supports it. Symptoms one to four hours after meals, prior gastric surgery, rapid nutrient transit, or a reproducible low plasma glucose during a mixed-meal test supports postprandial hypoglycemia.

What argues against it or keeps uncertainty open. Consistent overnight fasting episodes with endogenous hyperinsulinemia favors insulinoma or another fasting mechanism.

Discriminating next step. Use a supervised mixed-meal evaluation when the history is postprandial, avoid an oral glucose challenge, and tailor diet or treatment to the demonstrated mechanism.

The differential is ranked but not closed. Probability, consequence of delay, reversibility, and test burden are considered together. A dangerous alternative can deserve early exclusion even when it is not the statistically most likely explanation.

Evidence-gathering strategy#

• Document Whipple triad with plasma glucose. Compatible symptoms, a reliable low laboratory plasma glucose, and improvement after correction establish a hypoglycemic disorder more securely than a single home-meter value. Interpretation: Symptoms without low plasma glucose require alternate evaluation, while confirmed triad justifies mechanism testing and immediate safety planning.
• Obtain a critical sample during hypoglycemia. Glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and a comprehensive secretagogue screen distinguish endogenous secretion, administered insulin, drugs, and noninsulin mechanisms. Interpretation: The pattern must be interpreted at the moment of low glucose; normal values when euglycemic do not answer the mechanism.
• Assess organ, hormone, nutrition, and exposure causes. Kidney and liver function, infection, cortisol when indicated, weight, nutrition, alcohol, medicines, supplements, bariatric history, and household access identify noninsulin and exposure pathways. Interpretation: Suppressed insulin during illness directs treatment to substrate or hormone failure rather than pancreatic imaging.
• Use supervised fasting or mixed-meal testing selectively. A monitored fast captures suspected fasting events, while a mixed-meal study evaluates postprandial symptoms with immediate treatment capability. Interpretation: The provocation should reproduce the natural timing safely and stop at the diagnostic or safety threshold; unsupervised fasting is unsafe.
• Localize only after biochemical proof. CT, MRI, endoscopic ultrasound, nuclear or selective arterial studies seek a source after endogenous hyperinsulinism is established. Interpretation: A pancreatic lesion before biochemical confirmation may be incidental, while negative first-line imaging does not erase a valid biochemical diagnosis.

Tests are selected because they can change a decision, not because a broad panel feels comprehensive. Results are interpreted with their timing, pretest probability, measurement limitations, recent treatment, and the possibility that an apparently reassuring value was obtained too early or under the wrong conditions.

Progressive course and interpretation#

A supervised spontaneous episode confirms low plasma glucose with inappropriately high insulin, C-peptide, and proinsulin, suppressed ketones, and no secretagogue detected. This establishes endogenous hyperinsulinemic hypoglycemia; only then does targeted pancreatic localization begin, while discordant or negative imaging would not erase the biochemical diagnosis.

The trajectory is evidence. Improvement after an intervention may support a mechanism without proving it, while nonresponse should prompt a check of the diagnosis, delivery of the intervention, timing, adherence, and competing pathology. Discordant data should be explained rather than averaged away.

Management reasoning#

• Correct acute hypoglycemia immediately. Give oral glucose when safe or intravenous dextrose or glucagon when consciousness or swallowing is impaired, then recheck because recurrence can follow short-acting treatment.
• Prevent injury during investigation. Restrict driving, heights, water activities, hazardous work, and unsupervised fasting; provide rescue carbohydrate, glucagon when appropriate, identification, and a support-person plan.
• Treat the demonstrated cause. Remove a culprit drug, treat critical illness or adrenal insufficiency, use nutrition and medical therapy for postprandial disease, or pursue definitive insulinoma treatment after localization.
• Avoid diagnostic harm. Do not accuse based on access, perform localization before biochemistry, or order an unsupervised fast; review assay coverage and specimen timing when results conflict.
• Track recurrence and treatment response. Record time, meal relation, plasma glucose, critical-sample results, rescue use, weight, medicine access, and post-treatment events with a named endocrine follow-up plan.

Management remains proportional to severity and uncertainty. It includes explicit monitoring targets, foreseeable adverse effects, and stop or escalation conditions. Exact drug selection, dosing, and procedure details depend on verified individual factors, current local protocols, contraindications, and the responsible treating team; the analytical value here is the decision structure and its guardrails.

Communication and shared decisions#

Explain why symptoms and home-meter readings raise concern but do not establish the mechanism, and why the critical blood sample must be collected during low plasma glucose. Ask about household medicines, supplements, alcohol, work, and access without accusation, and clarify that pancreatic imaging before biochemical proof often finds unrelated lesions.

The communication task includes what is known, what remains uncertain, why the next step is recommended, what alternatives exist, and which change should trigger urgent reassessment. Teach-back, qualified interpretation when needed, accessible formats, and a named owner for pending results turn information into a safer plan.

Continuity and safety net#

• Use emergency help for seizure, unconsciousness, persistent confusion, injury, inability to swallow, recurrent low glucose after treatment, or symptoms while driving or alone.
• Treat symptoms promptly; do not delay glucose solely to complete testing when neurologic function is threatened, but obtain a critical sample first when it can be done safely and immediately.
• Do not fast alone or drive until the cause is controlled and a clinician has reviewed recurrence risk and the safety plan.
• Before discharge, confirm rescue glucose, glucagon when appropriate, activity restrictions, critical-sample instructions, medication security, pending drug tests, and who owns localization or hormone results.

Follow-through is verified, not assumed. The record should identify who receives each pending result, the time window for reassessment, the contingency if contact fails, and the clinical or functional outcome that will show whether the plan is working.

Equity and systems analysis#

Provide emergency glucose and a practical meal and activity safety plan, qualified interpretation, transportation for supervised testing, and discreet medication review without stigmatizing occupation, mental health, or household access. Do not make continuous-monitor ownership a requirement for diagnosis or safe care.

Access conditions belong in the causal model. Transportation, medication cost, work schedules, caregiving, health literacy, language, disability access, digital connectivity, and prior experiences of care can alter both the observed presentation and the feasibility of the plan. Addressing those constraints improves diagnostic validity as well as fairness.

Reasoning capabilities demonstrated#

• Confirms Whipple triad with laboratory plasma glucose and separates symptoms from meter error or nonhypoglycemic mimics.
• Interprets insulin, C-peptide, proinsulin, ketones, and secretagogue testing during low glucose to distinguish the major mechanisms.
• Recognizes neuroglycopenia, critical illness, adrenal failure, recurrent exposure, and unsafe fasting or driving as immediate hazards.
• Uses supervised fast or mixed-meal testing according to natural timing and performs pancreatic localization only after biochemical proof.
• Provides nonaccusatory exposure assessment, rescue treatment, activity restrictions, equitable testing access, and closed endocrine follow-up.

Key takeaways#

• Imaging cannot diagnose insulinoma before endogenous hyperinsulinemic hypoglycemia is established in a correctly timed critical sample.
• High insulin with low C-peptide suggests administered insulin, while high insulin with C-peptide requires secretagogue testing before assuming endogenous disease.
• Severe symptoms are treated immediately, and diagnostic sampling should never delay glucose when neurologic safety is threatened.